General Information:

Id: 3,794 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
male
Zucker fatty (fa/fa) and lean (fa/+) rats
article
Reference: Hsiao G et al.(2011) Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats Am. J. Physiol. Endocrinol. Metab. 300: E164-E174 [PMID: 20959535]

Interaction Information:

Comment Eighty-nine genes were differentially expressed in skeletal muscle from PPARgamma ligand-treated compared with fatty control (FC) rats. The study used functional analysis to identify muscle biochemical pathway alterations associated with PPARgamma ligand treatment. Several lipid metabolism ontology categories were enriched. All the genes annotated with lipid metabolism-related terms, as well as other related genes, were upregulated by ligand treatment (37 genes). Most of these are adipocyte-associated genes including acetyl-coenzyme A carboxylase (Acaca), a fatty acid elongase (Elovl6), fatty acid-binding proteins (Fabp4, Fabp5), hormone-sensitive lipase (Lipe), lipoprotein lipase (Lpl), and retinol-binding proteins (Rbp4, Rbp7). Pparg, highly expressed in adipocytes, was also increased (5.6-fold) after ligand treatment. Interestingly, genes overexpressed in FC vs. LC rats (Angptl4, Cd36, Fasn, and Scd1) were further overexpressed in the PPARgamma ligand-treated rats. Muscle tissue expression of adipocyte markers was induced by all the PPARgamma ligand treatments, and all the genes exhibited ligand treatment-specific modulation, except for Pparg.
Formal Description
Interaction-ID: 37593

drug/chemical compound

Thiazolidinedione

increases_expression of

gene/protein

PPARG

in skeletal muscle; in obese and lean Zucker rats
Drugbank entries Show/Hide entries for PPARG